Update on drug-eluting coronary stents
Update on drug-eluting coronary stents
复制标题
药物洗脱冠状动脉支架的最新进展
DOI：
10.1586/14779072.3.5.953
复制
发表时间：
2005
影响因子：
2
通讯作者：
J. Moses
中科院分区：
文献类型：
--
作者：
N. Kipshidze;M. Tsapenko;M. Leon;G. Stone;J. Moses
药物洗脱支架（DES）介入心脏病学实践的引入，导致了经皮冠状动脉介入治疗的长期疗效的显着改善。DES成功地结合了裸金属支架和稳定管腔的联合收割机机械优势，并将药物直接输送和受控洗脱至受损血管壁，以抑制进一步的新生内膜增殖。再狭窄的显著减少导致DES在临床实践中的应用，并迅速扩大了可成功治疗的冠状动脉疾病的范围，特别是在高危患者和复杂病变中。在这篇综述中，作者介绍了DES的最新数据。目前，在美国有两种类型的DES可用：西罗莫司洗脱支架（SES）CYPHER™（Cordis Corp.，FL，USA）和紫杉醇洗脱支架（PES）TAXUS™（Boston Scientific，MA，USA），以及更多正在审批中。除西罗莫司和紫杉醇外，其他几种药物已成功用于DES。依维莫司和ABT-578都是西罗莫司的类似物，也具有免疫抑制和抗增殖特性。DES开发的另一种方法是使用可以加速血管损伤后再内皮化和恢复正常内皮功能的药物。血管基因转移的最新进展也表明了心血管疾病的潜在新治疗方式，特别是在血管再狭窄的治疗中。
The introduction of drug-eluting stents (DES) to interventional cardiology practice has resulted in a significant improvement in the long-term efficacy of percutaneous coronary interventions. DES successfully combine mechanical benefits of bare-metal stents and stabilizing the lumen, with direct delivery and the controlled elution of a pharmacologic agent to the injured vessel wall to suppress further neointimal proliferation. The dramatic reduction in restenosis has resulted in the implementation of DES in clinical practice, and has rapidly expanded the whole spectrum of successfully treatable coronary conditions, particularly in high-risk patients and complex lesions. In this review the authors present current data on DES. Currently, two types of DES are available in the USA: sirolimus-eluting stents (SES) CYPHER™ (Cordis Corp., FL, USA) and paclitaxel-eluting stents (PES) TAXUS™(Boston Scientific, MA, USA), and many more are on the way to approval. In addition to sirolimus and paclitaxel, several other drugs have been successfully used in DES. Everolimus and ABT-578 are both analogs of sirolimus that also have immunosuppressive and antiproliferative properties. Another approach in the development of DES is to use drugs that can accelerate re-endothelialization and restore normal endothelial function following vascular injury. Recent advances in vascular gene transfer have also demonstrated potential new treatment modalities for cardiovascular disease, particularly in the treatment of vascular restenosis.
影响因子：
4.3
作者：
Faries, PL;Rohan, DI;LoGerfo, FW
通讯作者：
LoGerfo, FW